Abstract:Proton pump inhibitors (PPIs) are proven medications of choice for gastroesophageal reflux disease (GERD), acid-related disorders, erosive esophagitis, Barrett esophagus, prevention of gastrointestinal bleeding while on nonsteroidal anti-inflammatory drugs, eosinophilic esophagitis, peptic ulcer disease, stress ulcer prophylaxis in critically ill patients, and other indications. Best practice guidelines from several sources on the appropriate indications and duration of PPI therapy have been summarized for easy assimilation. Individualized decision with regard to PPI use is illustrated by case vignettes; best approaches are provided. The significant increase in use of PPIs for ill-defined indications over the years, associated adverse outcomes with long-term use, and consequent increase in health care costs have drawn much attention. Adverse outcomes due to PPI therapy may be categorized as unrelated or related to gastric acid inhibition. Examples of outcomes unrelated to acid inhibition include allergic reactions, acute interstitial nephritis, chronic kidney disease, poor cardiovascular outcomes, dementia, and drug interactions; consequences of acid inhibition include gastrointestinal infections, pneumonia, nutrient deficiencies, fractures, spontaneous bacterial peritonitis, and small intestinal bacterial overgrowth. Provider awareness regarding best practice guidelines on PPI use and imparting pertinent education to patients may be the rational approach to safe and effective PPI therapy. In individuals in whom the drug is not indicated, efforts at deprescribing the PPI may be attempted following discussion with the patient. Approaches include stopping the drug, reducing the dose or using "on-demand" therapy after completing the course of treatment for the specific indication. Barriers to successful deprescribing exist. Follow-up is recommended for recurrence of manifestations; in the event of recurrence, the PPI may need to be re-instituted. PPIs are valuable, irreplaceable drugs in the prevention and treatment of certain disorders for specific durations of time. Evidence nevertheless suggests that excessive and inappropriately prolonged use of PPIs is associated with a broad range of adverse effects. Education of provider and patient, stewardship, and motivation are key to appropriate use of PPIs for the right indications. Key implications for practice are offered.

Which is the best choice for gastroesophageal disorders: Melatonin or proton pump inhibitors?

Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial

Melatonin as a Mediator of the Gut Microbiota-Host Interaction: Implications for Health and Disease

Efficacy of proton pump inhibitor on nighttime reflux symptoms and associated sleep disturbances in patients with gastroesophageal reflux disease: A real-world study in northern China

The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis

Cost-effective Analysis of Proton Pump Inhibitors in Long-term Management of Gastroesophageal Reflux Disease: A Narrative Review

Meta-Analysis of the Effect of Proton Pump Inhibitors on Obstructive Sleep Apnea Symptoms and Indices in Patients with Gastroesophageal Reflux Disease

Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease

Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders: A Systematic Review and Meta-Analysis

Vonoprazan: A systematic review of an alternative to proton pump inhibitors

Low‐dose or Standard‐dose Proton Pump Inhibitors for Maintenance Therapy of Gastro‐oesophageal Reflux Disease: a Cost‐effectiveness Analysis

Treatment of Gastroesophageal Reflux Disease in Adults: An Individualized Approach

Improving treatment of people with gastro-esophageal reflux disease refractory to proton pump inhibitors

Comparative short-term safety and efficacy of hypnotics: A quantitative risk-benefit analysis

Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe

The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing

Melatonin Protects the Esophageal Epithelial Barrier by Suppressing the Transcription, Expression and Activity of Myosin Light Chain Kinase Through ERK1/2 Signal Transduction

Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors

Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review

Proton pump inhibitors from clinical pharmacists point of view